Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.

Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M.

Glycoconj J. 2013 Jul;30(5):511-22. doi: 10.1007/s10719-012-9451-9. Epub 2012 Oct 6.

PMID:
23053636
2.

First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.

Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.

J Immunol Methods. 2017 Nov;450:27-33. doi: 10.1016/j.jim.2017.07.005. Epub 2017 Jul 21.

PMID:
28735760
3.

Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.

Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y.

Front Cell Infect Microbiol. 2017 Apr 24;7:135. doi: 10.3389/fcimb.2017.00135. eCollection 2017.

4.

Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering.

Ihssen J, Haas J, Kowarik M, Wiesli L, Wacker M, Schwede T, Thöny-Meyer L.

Open Biol. 2015 Apr;5(4):140227. doi: 10.1098/rsob.140227.

5.

Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.

Hart PJ, O'Shaughnessy CM, Siggins MK, Bobat S, Kingsley RA, Goulding DA, Crump JA, Reyburn H, Micoli F, Dougan G, Cunningham AF, MacLennan CA.

PLoS One. 2016 Jan 7;11(1):e0145945. doi: 10.1371/journal.pone.0145945. eCollection 2016.

6.

Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.

Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M.

Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3016-21. Epub 2005 Feb 9.

7.

Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines.

Peng ZH, Pan C, Sun P, Feng EL, Wu J, Zhu L, Peng QZ, Wang HL.

Yi Chuan. 2015 May;37(5):473-9. doi: 10.16288/j.yczz.15-001.

PMID:
25998436
8.

A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.

Kothari N, Kothari S, Choi YJ, Dey A, Briles DE, Rhee DK, Carbis R.

Vaccine. 2015 Feb 4;33(6):783-8. doi: 10.1016/j.vaccine.2014.12.032. Epub 2014 Dec 26.

PMID:
25545593
9.

Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.

Ali A, An SJ, Cui C, Haque A, Carbis R.

Hum Vaccin Immunother. 2012 Feb;8(2):189-93. doi: 10.4161/hv.18350. Epub 2012 Feb 1.

PMID:
22426380
10.

Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.

Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A.

Vaccine. 2015 Jan 9;33(3):451-8. doi: 10.1016/j.vaccine.2014.11.030. Epub 2014 Nov 26.

11.

Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.

Robbins JD, Robbins JB.

J Infect Dis. 1984 Sep;150(3):436-49. Review.

PMID:
6207249
12.

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.

Clin Vaccine Immunol. 2007 Oct;14(10):1285-95. Epub 2007 Aug 8.

13.

A Salmonella typhi Vi conjugate vaccine.

Koul PA.

N Engl J Med. 2001 Aug 16;345(7):545-6. No abstract available.

14.
15.

Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.

Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S.

Hum Vaccin Immunother. 2016 Apr 2;12(4):939-45. doi: 10.1080/21645515.2015.1117715. Epub 2016 Feb 22.

16.

Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.

Pakkanen SH, Kantele JM, Herzog C, Kantele A.

Vaccine. 2014 Jan 23;32(5):544-51. doi: 10.1016/j.vaccine.2013.12.001. Epub 2013 Dec 14.

PMID:
24342246
17.
18.

Efficacy of purified Vi polysaccharide typhoid vaccine.

Park JH, Hong JJ, Choi ES, Lee JW, Park JH.

J Vet Sci. 2002 Jun;3(2):67-70.

19.

Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.

Pakkanen SH, Kantele JM, Rombo L, Kantele A.

Scand J Immunol. 2017 Oct;86(4):207-215. doi: 10.1111/sji.12583.

PMID:
28675263
20.

Structural insights from random mutagenesis of Campylobacter jejuni oligosaccharyltransferase PglB.

Ihssen J, Kowarik M, Wiesli L, Reiss R, Wacker M, Thöny-Meyer L.

BMC Biotechnol. 2012 Sep 24;12:67. doi: 10.1186/1472-6750-12-67.

Supplemental Content

Support Center